115 related articles for article (PubMed ID: 8379434)
1. Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma.
Flamand V; Sornasse T; Thielemans K; Demanet C; Leo O; Urbain J; Moser M
Adv Exp Med Biol; 1993; 329():611-6. PubMed ID: 8379434
[No Abstract] [Full Text] [Related]
2. A genetic approach to idiotypic vaccination for B cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of a spontaneous immune response against a B-cell lymphoma by dendritic cells leads to protection against the tumor.
Flamand V; Lespagnard L; Thielemans K; Leo O; Urbain J; Moser M
Ann N Y Acad Sci; 1993 Aug; 690():382-4. PubMed ID: 8368763
[No Abstract] [Full Text] [Related]
4. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
5. Useful and not-so-useful idiotypic images.
Köhler H; Raychaudhuri S
Prog Clin Biol Res; 1989; 288():223-33. PubMed ID: 2470109
[No Abstract] [Full Text] [Related]
6. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
7. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.
Siegel S; Wagner A; Schmitz N; Zeis M
Br J Haematol; 2003 Sep; 122(6):911-4. PubMed ID: 12956760
[TBL] [Abstract][Full Text] [Related]
8. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
[TBL] [Abstract][Full Text] [Related]
9. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
10. [A monoclonal antibody produced against the surface immunoglobulin of B-prolymphocytic leukemia].
López Nevot MA; Ruiz-Cabello F; Huelin C; Cabrera A; Garrido F
Sangre (Barc); 1986; 31(6):751-8. PubMed ID: 3551142
[No Abstract] [Full Text] [Related]
11. Antibody response after vaccination with antigen-pulsed dendritic cells.
Battaini F; Besusso D; Sfondrini L; Rossini A; Morelli D; Tagliabue E; Menard S; Balsari A
Int J Biol Markers; 2004; 19(3):213-20. PubMed ID: 15503823
[TBL] [Abstract][Full Text] [Related]
12. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells.
Turner MS; Cohen PA; Finn OJ
J Immunol; 2007 Mar; 178(5):2787-93. PubMed ID: 17312122
[TBL] [Abstract][Full Text] [Related]
13. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice.
Ge Y; Xi H; Zhang XG
Biomed Pharmacother; 2010 Sep; 64(7):487-92. PubMed ID: 20382498
[TBL] [Abstract][Full Text] [Related]
15. Idiotypic intramolecular help. Induction of tumor-specific antibodies by monoclonal anti-idiotypic antibody with the help of Fc-specific T helper clones.
Saeki Y; Chen JJ; Shi LF; Kohler H
J Immunol; 1989 Apr; 142(8):2629-34. PubMed ID: 2522964
[TBL] [Abstract][Full Text] [Related]
16. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
18. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients.
Engleman EG; Fong L
Clin Immunol; 2003 Jan; 106(1):10-5. PubMed ID: 12584045
[No Abstract] [Full Text] [Related]
19. Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells.
Kronenberger K; Dieckmann A; Selmayr M; Strehl J; Wahl U; Lindhofer H; Kraal G; Mocikat R
Blood; 2002 Feb; 99(4):1327-31. PubMed ID: 11830483
[TBL] [Abstract][Full Text] [Related]
20. Vaccination against lymphoma.
Zeis M
Haematologica; 2005 Jan; 90(1):3. PubMed ID: 15644302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
